Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GK01 Cell Injection in Advanced Malignant Solid Tumors
NCT07482319Phase 1Not yet recruiting
- Sponsor
- Beijing Geek Gene Technology
- Start
- Apr 2026
- Primary completion
- Dec 2026
- Modality
- Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GK01 in solid tumor (advanced stage), sponsored by Beijing Geek Gene Technology. Primary endpoints: Maximum Tolerated Dose at 28 days, Dose-Limiting Toxicity at 28 days and 1 more. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
GK01
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07482319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07482319.